To assess the effect of gadolinium (Gd) on the expression of several forms of cytochrome P450 (P450s) and antioxidant enzymes, we treated rats with gadolinium chloride (25 mg as Gd/kg body weight) 4 h after styrene (a multiple P450 inducer) treatment (600 mg/kg). Gd treatment significantly suppressed styrene-inducible cytochrome P4502B1 (CYP2B1), CYP2B2, CYP2E1, and CYP3A2 mRNA expressions to 48.6%, 69.8%, 61.1%, and 38.5%, accompanying with the reduction of proteins expression to 1.42%, 31.2%, 21.1% and 21.1%, respectively, compared with styrene alone treatment. Gd suppressed styrene-inducible CYP1A2 expression, but only at the protein level. On the other hand, styrene treatment caused a decrease in reduced form of glutathione (GSH), as well as increases in lipid peroxide and serum ALT and AST activities, suggesting the occurrence of hepatic damage probably due to styrene-induced oxidative stress in rat liver. Post-treatment of Gd attenuated this styrene-caused hepatic damage. Moreover, mRNA expressions of cellular antioxidant enzymes such as catalase, CuZn-superoxide dismutase (CuZnSOD) and glutathione peroxidase (GPX) were hardly changed by styrene and/or Gd treatment. In summary, Gd suppressed styrene-inducible expression of not only CYP2B1 but also several forms of P450 at both the mRNA and protein levels, along with attenuation of styrene-caused liver damage. These findings suggested that Gd is a chemo-preventive agent against hepatic damage caused by xenobiotics requiring biotransformation.
ABSTRACT
To assess the effect of gadolinium (Gd) on the expression of several forms of cytochrome P450 (P450s) and antioxidant enzymes, we treated rats with gadolinium chloride (25 mg as Gd/kg body weight) 4 h after styrene (a multiple P450 inducer) treatment (600 mg/kg). Gd treatment significantly suppressed styrene-inducible cytochrome P4502B1 (CYP2B1), CYP2B2, CYP2E1, and CYP3A2 mRNA expressions to 48.6%, 69.8%, 61.1%, and 38.5%, accompanying with the reduction of proteins expression to 1.42%, 31.2%, 21.1% and 21.1%, respectively, compared with styrene alone treatment. Gd suppressed styrene-inducible CYP1A2 expression, but only at the protein level. On the other hand, styrene treatment caused a decrease in reduced form of glutathione (GSH), as well as increases in lipid peroxide and serum ALT and AST activities, suggesting the occurrence of hepatic damage probably due to styrene-induced oxidative stress in rat liver. Post-treatment of Gd attenuated this styrene-caused hepatic damage. Moreover, mRNA expressions of cellular antioxidant enzymes such as catalase, CuZn-superoxide dismutase (CuZnSOD) and glutathione peroxidase (GPX) were hardly changed by styrene and/or Gd treatment. In summary, Gd suppressed styrene-inducible expression of not only CYP2B1 but also several forms of P450 at both the mRNA and protein levels, along with attenuation of styrene-caused liver damage. These findings suggested that Gd is a chemo-preventive agent against hepatic damage caused by xenobiotics requiring biotransformation.
Styrene is a widely used organic solvent, and personnel occupationally exposed to styrene can complain of behavioral deficits such as memory loss, fatigue, and mood swings. Styrene is a P450 inducible chemical in rat liver, and is metabolized to the toxic intermediate, styrene-7, 8-oxide (SO) (3) . Multiple P450s such as CYP1A2, CYP2B1, CYP2B2, CYP2E1 and CYP3A2 have been confirmed as styrene-inducible P450 isoforms in rat liver (6) . They have also been suggested to be involved in the metabolic biotransformation from styrene to SO (16, 17) . Styrene metabolite "SO" causes oxidative stress in its biotransformation process in the liver and lungs of experimental animals (23), concomitant with alterations of GSH and lipid peroxide levels (14, 21) , DNA adducts, strand breaks and micronuclei in mice lung (25) . Hence biotransformation of styrene to SO plays a crucial role.
Several studies have shown that pre-treatment with Gadolinium (Gd), a lanthanide rare earth element, alleviates acetaminophen-, CCl 4 -and ethanolinduced liver injury in rats (9, 13, 15) . Badger et al. (1) suggested that Gd serves as an alleviator of P450 induction. As well, the protective effect of Gd cages, maintained in an air-conditioned (23 ± 1°C) room with lighting on a 12 h light/dark cycle and a relative humidity of 40-70%, and provided ad libitum with chow from Clea (Tokyo, Japan) and tap water. Animals were allowed to adapt to the animal facilities for 1 week before use. Rats were randomly divided into 4 groups: styrene alone, styrene and Gd, Gd alone, and vehicle control (n = 3, in each group). The rats in both styrene-treated groups were intraperitoneally (ip) administered with styrene monomer (600 mg/kg) dissolved in corn oil.
To determine the effects of Gd on enzyme expression, gadolinium chloride was given ip 4 h after styrene injection at a dose of 25 mg/kg (as Gd) in an isotonic 0.9% NaCl solution. Control rats were given a 0.9% NaCl solution and corn oil in the same manner as the treatment groups. Twenty-four hours after styrene injection, all animals were anesthetized with diethyl ether and killed to obtain whole blood and fresh liver. The blood was allowed to coagulate at room temperature and was then centrifuged at 3000 rpm. Sera were stored at 4°C until assay. Immediately after bleeding, a portion of liver was removed and rinsed in autoclaved isotonic NaCl solution. The liver samples were cut into several small pieces (0.1~0.2 g) for mRNA expression analysis and GSH and lipid peroxide assay, promptly frozen in liquid nitrogen, and stored at −80°C until use. Remaining portions of liver were freshly processed for microsome isolation.
Preparation of hepatic microsome fraction. The hepatic microsome fraction was prepared by differential centrifugation. Fresh liver tissue was weighed and homogenized in four volumes of cold 0.1 M Tris-HCl (pH 7.4) containing 0.1 M KCl and 1 mM EDTA-Na 2 using a Potter Elvehjem homogenizer. Microsome fraction was then isolated by differential centrifugation. After the first centrifugation at 9000 g for 20 min, the supernatant was centrifuged at 105000 g for 60 min. The pellets were suspended in homogenizing buffer and further centrifuged at 105000 g for 60 min. The final pellet containing the microsome fraction was resuspended in 0.1 M TrisKCl buffer containing 20% glycerol, frozen in liquid nitrogen, and stored at −80°C until use.
RNA preparation and first strand cDNA synthesis. Total RNA was isolated from a small piece (~0.1 g) of liver using 1 mL of ISOGEN, followed by isopropanol precipitation. The RNA pellet was dissolved in DEPC-treated water and stored at −80°C until use. Approximately < 30 μg of total RNA was is specifically involved in the inhibition of CYP2E1 in ethanol-treated rats (9) . As well as CYP2E1 inhibition, several studies have reported that Gd-caused suppression of glucuronide conjugation (19) , glutathione S-transferase, and epoxide hydrolase gene expression (11) . Thus, Gd may affect various types of enzymes; however, it is not clear whether Gd modulates the induction of other different forms of P450 except for CYP2E1; or whether Gd affects the expression of a variety of antioxidant enzymes, reflecting a redox status.
In the present study, to elucidate the suppressive effect of Gd on styrene-inducible multiple forms of P450s and the protective effect of Gd against styreneinduced hepatic damage we analyzed five forms of P450s at the mRNA and the protein expression levels and evaluated primary cellular oxidative damage. We also determined antioxidant enzyme expression to clarify whether Gd affected the redox status altered by styrene treatment.
MATERIALS AND METHODS

Materials.
Styrene monomer (purity: 99%) and GdCl 3 ·6H 2 O (purity: 99.9%) were purchased from Nacalai tesque (Kyoto, Japan). GSH (purity: 97%) and thiobarbituric acid (purity: 98%) were purchased from WAKO Pure Chemicals (Tokyo, Japan). Polyclonal rabbit anti-rat CYP1A1/2 and CYP2E1 antibodies were purchased from Chemicon (CA, USA). Polyclonal goat anti-rat CYP2B1 and rabbit anti-rat CYP3A2 antibodies were purchased from Daiichi Pure Chemicals (Tokyo, Japan). The antibodies against rat CYP1A1/2 and CYP2E1 showed no cross reactivity with other P450 isoforms. The antibodies against rat CYP2B1 and CYP3A2 crossreacted with CYP2B2 (CYP2B1/2) and CYP2C6 (CYP3A2/2C6), respectively. Secondary antibodies, horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-goat immunoglobulin (IgG), were purchased from DAKO (Kyoto, Japan). ISOGEN and RNase-free DNase I for RNA extraction were purchased from Nippon Gene (Toyama, Japan). The first strand cDNA synthesis kit for RT-PCR (AMV), Expand High Fidelity Plus PCR system, and LightCycler Fast Start Kit SYBR GI were purchased from Roche Diagnostics (Mannheim, Germany). The PCR gel purification kit was purchased from Qiagen (Tokyo, Japan).
Animals and experimental design. Seven-week-old male Sprague-Dawly rats were purchased from Nippon SLC (Hamamatsu, Japan). They were housed in initial denature at 95°C for 10 min, 2) 35 cycles of amplification consisting of denaturation at 95°C for 10 s, annealing at each primer-pair-specific temperature for 5 s, and elongation at 72°C for fragment size depending on seconds calculated from 1 s per 25 bases. The mRNA concentration was calculated using LightCycler System software. A standard curve was obtained from the standard solution corresponding to each P450. Standard solutions for LC-PCR were prepared by purifying PCR fragments using a gel purification kit and purity was then confirmed by checking A260/A280 ratios exceeding 1.7 and the concentrations at 260 nm before use in LC-PCR. The P450 mRNA level of each sample was standardized based on the concentration of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) measured as the internal control.
purified with RNase-free DNase I to remove genomic DNA contaminated in the total RNA sample solution. The concentration of purified total RNA was determined by spectrophotometer. The 1.5 μg of purified total RNA was reverse-transcribed to first strand complementary DNA (cDNA) at 42°C, using a first strand cDNA synthesis kit for RT-PCR (AMV).
Real-time quantitative LightCycler PCR (LC-PCR)
for evaluating cytochrome P450 expression. Hepatic P450 mRNA concentrations were measured by LC-PCR, using specific primer pairs listed in Table 1 and a LightCycler Fast Start DNA Master SYBR GI kit. The 20 μL of PCR reaction mixture was prepared with 2 μL of PCR master, 4 mM of MgCl 2 , 0.5 μM of each primer pair, and 1 μL of cDNA sample solution corresponding to 50 ng of total RNA. LC-PCR amplification conditions were as follows: 1) Fisher's protected least significant difference (PLSD) using STAT View 4.5.1 (Berkeley, USA). p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Gd inhibition of several P450 isoforms induction by styrene treatment
Styrene treatment (600 mg/kg body weight) to rats specifically induced hepatic CYP2B1 by 47-fold compared with the controls (p < 0.01), consistent with our previous observation (6) . Following CYP2B1 expression, significant increases in CYP2E1, CYP1A2, and CYP2B2 mRNA expression (3-fold (p < 0.01), 1.7-fold (p < 0.01), and 1.7-fold (p < 0.05) higher than controls, in order) were observed (Fig. 1) . Styrene also increased CYP3A2 mRNA expression, but not significantly. Western blot analyses indicated clear increases in these five isoforms of P450 at a protein level, corresponding to each mRNA expression (Fig. 2 ). P450s such as CYP2E1, CYP2B1/2, and CYP2C11/6 have been suggested to contribute to biotransformation of styrene to SO (16) . They have also been suggested to induce oxidative stress by generating reactive oxygen species (ROS) including superoxide radical and hydrogen peroxide, followed by formation of hydroxyl radical (5, 8) . Therefore, styrene toxicity might be involved in these P450 enzymes induced in the biotransformation process of styrene.
Post-treatment with Gd (25 mg/kg body weight) significantly inhibited the expression of styreneinducible P450 isoforms at both the mRNA and protein levels in rats ( Figs. 1 and 2) . CYP2B1, CYP2B2, CYP2E1, and CYP3A2 mRNA expression, but not CYP1A2, were decreased by posttreatment of Gd to 48.6%, 69.8%, 61.1%, and 38.5%, respectively, of the individual levels in the styrene-treated groups. The protein expressions of these 4 isoforms were also inhibited by post-treatment of Gd to 1.42% (in CYP2B1), 31.2% (in CYP2B2), 21.1% (in CYP2E1), and 21.1% (in CYP3A2) of the individual levels observed in styrene treated groups. CYP1A2 was diminished only at the protein level, to 13.0% of the styrene treated groups. Gd has been reported to moderate ethanolinducible CYP2E1 in rats (9) . However, the present study demonstrated that Gd inhibits different isoforms of P450 as well as CYP2E1.
Protection by Gd treatment against styrene-induced hepatotoxicity CYP2B1, CYP2E1, and CYP3A2 are considered to Two-step semi-quantitative RT-PCR for antioxidant enzyme mRNA expression. Two-step semi-quantitative RT-PCR (2-step RT-PCR) was conducted for CuZnSOD, GPX, and catalase mRNA expression analyses. First strand cDNA sample solutions were subjected to 2-step RT-PCR using a conventional PCR thermal cycler. GAPDH was used as the internal control. PCR was conducted using 1 μL of cDNA solution corresponding to 50 ng of total RNA, 0.5 μM of specific primer pairs listed in Table 1, and PCR reagents included in an Expand High Fidelity PCR system kit, with a total reaction volume of 20 μL. The number of PCR cycles was set at 25 for CuZnSOD, 34 for GPX, 27 for catalase, and 28 for GAPDH, to avoid saturation of the amplification reaction. The amplification conditions are summarized in Table 1 . The amplified products were separated and visualized by 2.5% agarose gel electrophoresis containing ethidium bromide.
Western blot analysis of P450 proteins. The microsome protein content of each sample was determined according to a method described by Lowry et al. (12) . Hepatic microsomes containing 1-2 μg of protein were separated on 9% SDS-PAGE and transferred to a polyvinylidene difluoride membrane from Millipore (MA, USA) by semidry blotting. Membranes were incubated with the first antibodies to rat CYP1A2 (1 : 10000), CYP2B1/2 (1 : 20000), CYP2E1 (1 : 10000), and CYP3A2 (1 : 20000) individually overnight at 4°C, followed by incubation with HRP-conjugated secondary IgG. Blots were developed in an ECL Western blotting system from DuPont (Boston, USA), and chemiluminescence was recorded using X-ray film. To distinguish CYP1A1/2, CYP2B1/2, and CYP3A2/2C6, hepatic microsomes were prepared by methylcholanthrene or phenobarbital treatment to rats in separate experiments and used as specific markers in SDS-PAGE.
Assay of serum enzymes, hepatic GSH, and lipid peroxidation. Serum alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) activities were assayed using a diagnostic kit from Alfresa Pharma (Osaka, Japan), according to the manufacturer's protocol. The reduced form of glutathione (GSH) was determined in the liver homogenates according to the previous method (7). Hepatic lipid peroxide was determined in liver homogenates by assaying thiobarbituric acid reactive substances according to a previously described method (18) .
Statistics. Statistical analyses were conducted by cause increases of NADPH-dependent microsomal lipid peroxide that can in tern cause liver damage (8, 9) . Imaoka et al. (8) have suggested that hydroxyl radical formation and oxygen consumption of P450 were strongly exhibited by these P450 isoforms. Hence, inhibition of several kinds of styrene-inducible P450 isoforms seemed to contribute to attenuation of styrene-causing hepatic damage in rats. To elucidate the effect of Gd on hepatic damage from styrene, serum AST and ALT activities were determined. As shown in Fig. 3 , AST activity was significantly increased to 273 IU/L by styrene treatment alone, which was 3-fold higher than the controls. This increase was significantly inhibited by posttreatment of Gd to 192 IU/L (70% level of the styrene alone group (p < 0.05)). Although styrene increased ALT activity to 72.5 IU/L (approximately 1.7-fold higher than the controls), this increase significantly recovered to the control level by posttreatment of Gd (p < 0.01). Treatment by Gd alone elevated both AST and ALT activities to 1.8-and 1.2-fold, respectively, compared with controls, but these were not statistically significant. Thus, improvement of AST and ALT activities was observed in the styrene/Gd group, suggesting the protective effect of Gd against the hepatic damage caused by styrene treatment to rats.
Inhibition by Gd against oxidative stress
In general, changes in hepatic GSH and lipid peroxide levels are thought to be good indices to clarify Fig. 1 Effects of GdCl 3 on styrene-inducible P450 mRNA expression in rat liver. LC-PCR analyses of CYP1A2, CYP2B1, CYP2B2, CYP2E1, and CYP3A2 mRNA expression were performed as described in "MATERIALS AND METHODS". The mRNA expression level of each P450 gene was normalized to the expression value of housekeeping gene GAPDH used as the internal control, and standardized to the corresponding control value. Data are presented as means ± SD. § and § §: significantly different from the controls at p < 0.05 or p < 0.01, respectively. indicates comparison between the styrene-only and styrene + Gd(III) group; significantly different at p < 0.05. Fig. 2 Effects of GdCl 3 on styrene-inducible P450 enzyme expression in rat liver. Western blot analyses of CYP1A2, CYP2B1, CYP2B2, CYP2E1, and CYP3A2 were performed as described in "MATERIALS AND METHODS". Hepatic microsomes (2 µg/lane for CYP1A2 and CYP2E1, 1 µg/lane for CYP2B1/2 and CYP3A2) were separated by 9% SDS-PAGE followed by immunostaining using the corresponding specific P450 antibodies and detected by ECL.
respectively, of the controls, suggesting that Gd improved the redox status aggravated by styrene treatment.
It is considered that the main sources of hepatic ROS generation are P450 enzymes, mitochondria and Kupffer cells, and that the elevated cellular oxygen radicals consequently affect hepatic GSH and lipid peroxide (2, 4, 14, 26) . Our results suggested that post-treatment with Gd could contribute to an improvement in the redox status altered by styrene treatment, and eventually would contribute to protection of rat liver from styrene damage through alleviating styrene-inducible P450 expressions such as CYP1A2, CYP2B1/2, and CYP3A2 ( Figs. 1 and 2) , as well as CYP2E1, as previously reported (9) . the occurrence of oxidative stress from xenobiotics. In the present study, we determined whether Gd treatment improved GSH content and lipid peroxide aggravated by styrene treatment in rat liver. Styrene treatment caused a significant decrease in GSH to 70.6%, and a significant increase in lipid peroxide to 163.7% of the controls (Fig. 4) , consistent with previous findings that styrene inducing oxidative stress occurs in its biotransformation process concomitant with the decrease in GSH levels (14, 24) . As shown in Fig. 4 , Gd alone treatment hardly changed either GSH or lipid peroxide level. However, the increased GSH and lipid peroxide levels induced by styrene were significantly recovered by post-treatment with Gd, to 87.5% and 146.7%, Fig. 3 Effects of GdCl 3 on styrene-induced hepatic damage in rats. Serum samples were collected and AST and ALT activities were analyzed as described in "MATERIALS AND METHODS". Data are presented as means ± SD. § and § §: significantly different from the controls at p < 0.05 or p < 0.01, respectively. and indicate comparisons between the styreneonly and styrene/Gd(III) group; significantly different at p < 0.05 and p < 0.01, respectively. Fig. 4 Effects of GdCl 3 on hepatic GSH and lipid peroxide contents in rats. Rat livers were homogenized and used for assays as described in "MATERIALS AND METHODS". Data are presented as means ± SD. § and § §: significantly different from the controls at p < 0.05 or p < 0.01, respectively. and indicate comparisons between the styrene-only and styrene/ Gd(III) group; significantly different at p < 0.05 and p < 0.01, respectively.
Effect of Gd on antioxidant enzymes
It is well-known that ROS and antioxidant enzymes such as SOD, catalase, and GPX are maintained in a dynamic balance under normal physiological conditions. But a variety of chemicals including xenobiotics disrupt the balanced condition, and cells are then damaged by oxidative stress (22) . To determine the status of antioxidant enzymes, which are probably modulating the oxidative stress after styrene and or Gd treatment, we analyzed mRNA expression of CuZnSOD, GPX, and catalase by 2-step RT-PCR. Despite the occurrence of styrene inducing oxidative stress shown by alterations of GSH and lipid peroxide (Figs. 3 and 4) , expressions of CuZnSOD, catalase, and GPX were hardly altered at the mRNA level in the group given styrene alone (data not shown).
When the cellular hydrogen peroxide level is particularly high, catalase and GPX activity are enhanced (10), but SOD is exerted at a low level by enhanced hydrogen peroxide (20) . Several forms of P450 such as CYP2B1/2, CYP2E1, CYP3A2, and CYP1A2 have been suggested to generate the majority of the hydroxyl radicals, because P450 generating superoxide radical is rapidly converted to hydroxyl radical via hydrogen peroxide under the catalytic effect of iron (8) . Based on these previous findings, we suggest that antioxidant enzymes mRNA expression remained unaltered by extremely enhanced hydroxyl radical formation due to styreneinducible multiple P450 expression.
In conclusion, in rats, post-treatment of Gd suppressed styrene-inducible forms of P450 such as CYP2B1, CYP2B2, CYP2E1, and CYP3A2 at both mRNA and protein levels. It also alleviated styrenecaused hepatic damage, suggesting an improvement of the redox status aggravated by styrene treatment. These results suggested that changes in P450 are important factors for Gd to confer protection for the liver. Therefore, our findings suggested that Gd is a chemo-preventive agent against hepatic damage caused by xenobiotics requiring biotransformation.
